Huadong Medicine’s HDM2017 Wins FDA Orphan Drug Designation – CDH17 ADC Targets Three Gastrointestinal Cancers
Huadong Medicine Co., Ltd (SHE: 000963) announced that HDM2017, its independently developed CDH17-targeting antibody-drug conjugate...
Hengrui’s SHR-2524 Wins NMPA Phase I Approval – Novel Subcutaneous Formulation Plus Bevacizumab Targets First-Line Liver Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced NMPA clearance to initiate a...
Boehringer Ingelheim’s Jascayd (Nerandomilast) Launches in Shanghai – First PDE4B Inhibitor for Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim announced the first prescription issuance for Jascayd (nerandomilast tablets) in Shanghai, marking the...
Huadong Medicine’s HDM2024 Wins FDA Phase I Approval – First-in-Class EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors
Huadong Medicine Co., Ltd (SHE: 000963) announced that HDM2024, a Category 1 innovative bispecific antibody-drug...
Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029
The WHO Foundation and Eli Lilly and Company (NYSE: LLY) announced a strategic partnership to...
J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer
Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved a...
Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia
Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that ABSK061, its self-developed highly selective small-molecule FGFR2/3...
Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the nationwide commercial launch of Zesuning (injectable...
Fosun Pharma’s Tenapanor (Vteglea) Issues First China Prescription – NHE3 Inhibitor Targets Hyperphosphatemia in Dialysis Patients
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced the first prescription issuance...
Pfizer’s Tilrekimig Hits Phase 2 Primary Endpoint – IL-4/IL-13/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study of tilrekimig...
FDA Accepts ENHERTU sBLA with Priority Review – HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction
AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. FDA has...
J&J Files TECVAYLI Line Extension with EMA – BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma
Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a Type II variation application...
HighTide Therapeutics’ HTD1801 NDA Accepted by NMPA – First-in-Class AMPK/NLRP3 Dual-Target Drug for Type 2 Diabetes
HighTide Therapeutics Inc. (HKG: 2511) announced that China’s National Medical Products Administration (NMPA) has accepted...
AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences
AstraZeneca (AZ, NASDAQ: AZN) announced the initiation of CLARITY-Gastric 02, a multi-center, randomized, controlled Phase...
Bayer Co.Lab Adds Arbele and Alphelix – China Innovation Cluster Reaches 12 Resident Biotech Startups
Bayer Co.Lab announced that Arbele Limited and Alphelix Bioscience have joined its co-creation platform, bringing...
FDA Approves GSK’s Wellcovorin for Cerebral Folate Deficiency – First Treatment for Rare FOLR1 Genetic Disorder
The U.S. Food and Drug Administration (FDA) approved expanded use of GlaxoSmithKline’s (GSK, NYSE: GSK)...
Astellas’ XOSPATA Fails Phase III Primary Endpoint in Frontline AML – FLT3 Inhibitor Misses OS Benefit vs. Midostaurin
Astellas Pharma Inc. (TYO: 4503) and the HOVON Foundation announced that the Phase III HOVON...
Keymed Biosciences Initiates CMG901 Phase III – AstraZeneca Triggers $45 Million Milestone for Claudin 18.2 ADC
Keymed Biosciences Inc. (HKG: 2162) announced the initiation of Phase III clinical trials for CMG901,...
SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure
SicaGene (Beijing) Biotechnology Co., LTD announced that SG12 injection, a self-developed antisense oligonucleotide (ASO), has...
Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that SKB575/HBM7575, a long-acting bispecific antibody (bsAb)...